Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Indications of a considerable decrease in the death rate in mycosis fungoides by PUVA treatment

G Swanbeck1, G Roupe, M H Sandström

  • 1Department of Dermatology, Sahlgrenska University Hospital, Göteborg, Sweden.

Acta Dermato-Venereologica
|November 1, 1994
PubMed
Summary

This study examined mycosis fungoides mortality rates in Sweden from 1961-1990. Data was collected to assess if PUVA (psoralen plus ultraviolet A) therapy impacts survival rates for this condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognosis and prognostic factors in adult patients with atopic dermatitis: a long-term follow-up questionnaire study.

The British journal of dermatology·2004
Same author

Atopy patch test reactions to Malassezia allergens differentiate subgroups of atopic dermatitis patients.

The British journal of dermatology·2003
Same author

[Skin of the aging human being].

Lakartidningen·2001
Same author

Microdialysis of histamine in the skin of patients with mastocytosis.

Experimental dermatology·2001
Same author

Stronger association with HLA-Cw6 than with corneodesmosin (S-gene) polymorphisms in Swedish psoriasis patients.

Archives of dermatological research·2001
Same author

Cytogenetic studies in patients with mastocytosis.

Cancer genetics and cytogenetics·2000

Area of Science:

  • Dermatology
  • Oncology
  • Public Health

Background:

  • Psoralen plus ultraviolet A (PUVA) therapy has been used for mycosis fungoides since the mid-1970s.
  • The efficacy of PUVA in treating mycosis fungoides is recognized, but its impact on mortality remains unclear.
  • Ethical considerations have precluded controlled clinical trials on PUVA's effect on survival.

Purpose of the Study:

  • To investigate the mortality rate of mycosis fungoides in Sweden between 1961 and 1990.
  • To gather data relevant to determining if PUVA therapy influences the death rate associated with mycosis fungoides.
  • To provide epidemiological insights into mycosis fungoides survival trends.

Main Methods:

  • Retrospective analysis of mortality statistics in Sweden.

Related Experiment Videos

  • Focus on the period from 1961 to 1990, encompassing pre- and post-PUVA therapy eras.
  • Utilizing Sweden's reliable national death statistics for a rare but conspicuous disease.

    • Main Results:

    • Data on mycosis fungoides mortality rates in Sweden from 1961 to 1990 was compiled.
    • The study aimed to establish baseline mortality data before widespread PUVA adoption.
    • Analysis intended to correlate mortality trends with the introduction of PUVA therapy.

    Conclusions:

    • The study provides crucial data on mycosis fungoides mortality trends in Sweden.
    • Findings are intended to inform discussions on the overall impact of PUVA therapy on patient survival.
    • This research contributes to understanding the long-term outcomes of mycosis fungoides management.